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Background: Subarachnoid hemorrhage (SAH) is a neurological emergency with limited pharmacological
treatment options. Inflammation is increasingly recognized as a key pathogenic contributor to brain injury in this
condition. In the present study, we examined the neuroprotective effects of the immunomodulatory agent,
fingolimod, in rats subjected to SAH.
Methods: We utilized an endovascular rat perforation model of SAH. Animals were divided into four groups:
(1) sham-vehicle; (2) sham-fingolimod; (3) SAH-vehicle; and (4) SAH-fingolimod. Rats received either vehicle solution or
fingolimod (0.5 mg/kg) intraperitoneally 3 hours after sham surgery or SAH. A closed cranial window and intravital
microscope system was used at 48 hours to assess neuroinflammation, which was represented by rhodamine-6G-
labeled leukocyte trafficking in pial venules, and pial arteriolar dilating responses to a variety of vasodilators, including
hypercapnia, and topically-applied acetylcholine, adenosine, and S-nitroso-N-acetyl penicillamine. In addition,
motor-sensory function was evaluated.
Results: Compared to sham-vehicle rats, SAH-vehicle animals displayed a four-times greater increase in pial venular
intraluminal leukocyte adhesion. Treatment with fingolimod largely reduced the intravascular leukocyte adhesion.
Vehicle-treated SAH animals displayed a significant decrease in pial arteriolar responses to all the vasodilators tested
and vascular reactivity was preserved, to a significant degree, in the presence of fingolimod. In addition, neurological
scores obtained at 48 hours post-SAH indicated significant neurological deficits in the vehicle-treated group (versus
sham-vehicle surgical control). Those deficiencies were partially reduced by fingolimod (P < 0.0001 compared to the
vehicle-treated SAH group).
Conclusions: Treatment of rats with fingolimod was associated with a marked limitation in the intravascular adhesion
of leukocytes to pial venules, preserved pial arteriolar dilating function, and improved neurological outcome in rats
subjected to SAH.
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Subarachnoid hemorrhage (SAH) is associated with a
disproportionately elevated morbidity and mortality. The
overall case fatality is estimated in 40 to 50% with almost
10 to 15% of the patients dying before reaching medical
attention [1,2]. Of the survivors, 46% may have long-
term cognitive impairment and 30% require lifelong sup-
portive care [3,4]. This condition often affects young* Correspondence: testai@uic.edu
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unless otherwise stated.adults and may be responsible for almost a quarter of all
the years lost because of stroke [5]. Despite intense re-
search, progress toward the development of effective
treatments for SAH has been disappointingly slow.
Nimodipine remains the only pharmacological treatment
for this condition. The beneficial effect of nimodipine,
however, is limited and its use is often restricted by the
occurrence of hypotension [6]. New and effective treat-
ments for SAH are largely needed. Studies performed
over the past decade have yielded a preponderance of
evidence supporting a link between inflammation and
stroke outcome [7-10]. Inflammation plays an importantis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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minished vascular reactivity, microthrombosis, and en-
hanced blood brain barrier (BBB) permeability [7,8,11,12].
These observations support immunomodulation as a po-
tential target for intervention following SAH. Fingolimod
(FTY720) is an immunomodulatory agent has been ap-
proved by the Food and Drugs Administration (FDA) for
the treatment of multiple sclerosis. Fingolimod is a
sphingosine-1-phosphate (S1P) analog that crosses the
BBB and regulates critical cellular processes including pro-
liferation, apoptosis, endothelial barrier permeability, and
inflammation [13,14]. Studies performed in association
with cerebral ischemia and intraparenchymal hemorrhage
have shown that FTY720 reduces stroke-related neuroin-
flammation, brain edema, and neuronal death and improves
neurological outcome [15-17]. Thus, we hypothesized that
fingolimod would be efficacious in the treatment of SAH.
To that end, we investigated the effect of FTY720 in a rat
model of SAH. In particular we addressed leukocyte adhe-
sion to pial venules, microvascular (pial arteriolar) dilating
reactivity, and neurological outcome.
Methods
Drugs and SAH model
FTY720 was supplied by Cayman Chemicals (Ann Arbor,
MI, USA). Experimental protocols were approved by the
institutional Animal Care and Use Committee of the
University of Illinois at Chicago. Sprague–Dawley male
rats (250 to 300 g) were randomly assigned to the sham-
vehicle (n = 10), sham-FTY720 (n = 10), SAH-vehicle
(n = 11), or SAH-FTY720 (n = 11) groups. We utilized the
endovascular perforation model of SAH as previously de-
scribed [18]. Briefly, animals were anesthetized with 2%
isoflurane and mechanically ventilated. Physiological vari-
ables, including blood pressure, blood gases, and body
temperature, were continuously monitored and kept
within physiological ranges. Regional cerebral blood flow
(rCBF) was monitored before, during, and after SAH by
Laser Doppler flowmetry (LDF), which entailed attach-
ment of a laser-Doppler probe to the skull over the right
middle cerebral artery (MCA) territory. The right internal
(ICA) and external carotid arteries (ECA) were isolated to
their origins at the common carotid artery (CCA) bifur-
cation. The ECA was ligated and shaped into a short
stump. The CCA was temporary clipped, and a hollow
polytetrafluoroethylene (PTFE) tube was advanced ros-
trally into the ICA from the ECA stump until resistance
was felt, and then a tungsten wire was partially advanced
through PTFE tube to perforate the bifurcation of the an-
terior and middle cerebral arteries. Immediately after
puncture, the PTFE tube and tungsten wire were retracted
into the ECA stump, and the ICA was reperfused. The in-
cision was then closed with nylon monofilament suture,
and rats were extubated and returned to their cages. SAHwas determined by a transient drop in cerebral blood flow
of > 95% and confirmed by post-mortem examination
which was performed at 48 hours post-surgery. Blood ac-
cumulation at the circle of Willis indicates a successful
vessel perforation. Similar surgical procedure was per-
formed in sham-vehicle and FTY720 groups except that
the suture was removed once resistance was felt and no
tungsten wire perforation was performed. To minimize
factors that may influence bioavailability we used the in-
traperitoneal (IP) route. Animals were treated with vehicle
or FTY720 (0.5 mg/kg) at 3 hours after surgery.Peripheral leukocyte count
The effect of FTY720 on leukocytes was determined
using peripheral blood samples. Animals were randomly
assigned to sham-vehicle (n = 3), sham-FTY720 (n = 5),
SAH-vehicle (n = 5), and SAH-FTY720 (n = 4) groups.
Blood samples were collected before (baseline) and 48
hours after surgery. An additional non-surgical naïve
control group was used to confirm the immonomodula-
tory effect of FTY720. A total of 0.5 ml of blood was ob-
tained from the subclavian vein, placed in a Microtainer
tube coated with K2-EDTA (BD Biosciences, San Jose,
CA, USA), and analyzed using an automated hematology
analyzer Advia 120 (Siemens, Dublin, Ireland).Cranial window installation
Cranial windows were installed 48h after surgery as
previously described. Briefly, bilateral femoral arterial
and venous catheters were placed with the rats under 2%
isoflurane/70%N2O/30%O2 anesthesia, paralyzed with
curare (1 mg/kg intravenously) and supported with
mechanical ventilation. Femoral artery and vein were
canulated for arterial blood pressure monitoring and
arterial blood gas measurement. Body temperature was
kept at 37°C. The animal was positioned on a stereotac-
tic frame and a 10 mm craniotomy was performed over
the skull midline. The dura was removed carefully to
keep the sagital sinus intact. An 11 mm in diameter and
1.5 mm in thickness borosilicate glass window equipped
with 3 ports was glued to the skull. The time from dural
excision to sealing of the cranial window was minimized
(less than 5 minutes) to avoid complications from brain
swelling and damage at the dural edge. The intracranial
pressure (ICP) under the cranial window was monitored
thorough the experiment using the ICP measurement
port. Artificial CSF (aCSF) was suffused into the cranial
window and the effusion rate was adjusted to maintain
an ICP of 7 to 11 mmHg in all groups. After completion
of the surgery, the anesthesia with isoflurane was switched
to fentanyl infusion for monitoring of rhodamine-6G
(R6G) leukocyte labeling and the assessments of pial
arteriolar responses.
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Leukocyte behavior analyses were performed 48 hours
after surgery by infusing R6G as previously described
[19]. This is a semiquantitative method used for the
in vivo assessment of leukocyte trafficking. Fluorescence
area of R6G-labeled leukocytes adhered to the vessel
wall (this includes both tightly-adhered and slow-rolling
leukocytes) is used as a surrogate marker of neuroin-
flammation. Animals were anesthetized with 70% N2O/
30% O2 - fentanyl (25 μg/kg/h, intravenously). After cra-
nial window placement, R6G (0.2 mg loading dose) was
applied intravenously to sham-vehicle, sham-FTY720,
SAH-vehicle, and SAH-FTY720 groups, followed by 0.2
mg/h maintenance dose (n = 6 per group). Pial venules
ranging from 40 to 80 μm in diameter were randomly
selected. R6G-labeled stationary leukocytes were viewed
and captured using a digital camera (CoolSnap ES, Pho-
tometrics, Tucson, AZ, USA) mounted on a fluorescence
microscope (Nikon, Melville, NY, USA) equipped with
an epi-illumination dark field system. Images were ob-
tained 60 minutes after initiating R6G infusion and ana-
lyzed using MetaMorph software (Molecular Devices,
Downingtown, PA, USA). R6G dosage, intravenous suf-
fusion time, and laser light source were applied in iden-
tical manner to each animal, minimizing the variations
in leukocyte labeling. Using this technique, only adher-
ent leukocytes can be detected [20]. Leukocyte adhesion
was reported as the % of adherent leukocytes occupying
the viewed venular area in the microscopic field.
Arteriolar reactivity
Vascular reactivity was determined 48 hours after SAH
by measuring pial arteriolar diameter changes in response
to different vasodilating stimuli, including hypercapnia,
acetylcholine (Ach, 10 μM and 100 μM), adenosine (ADO,
10 μM and 100 μM), and S-nitroso-N-acetyl penicillamine
(SNAP, 0.1 μM and 1 μM) as previously described [19,21].
Briefly, animals were randomly assigned to the sham-
vehicle, sham-FTY720, SAH-vehicle, and SAH-FTY720
groups (n = 5 to 6 per group). Pial arteriolar diameters
were measured through a cranial window after 40 minutes
of suffusion of aCSF (baseline) and again after 3 minutes
of hypercapnia (PaCO2 at approximately 70 mmHg). CO2
reactivity was calculated as the percentage of diameter in-
crease per mmHg of PaCO2 change. Fifteen minutes after
return to baseline, Ach, ADO, and SNAP were sequen-
tially suffused in the space under the cranial window at
the concentrations indicated. Diameter values from three
arteriolar segments were obtained and averaged.
Neurological assessments
These were done at 48 hours post-SAH by a blinded ob-
server prior the placement of the cranial window. We
utilized a 21-point scale as previously described [20].Briefly, animals were randomly assigned to the sham-
vehicle, sham-FTY720, SAH-vehicle, and SAH-FTY720
groups (n = 10 to 11 per group). The ratings were taken
from a sum of scores from 7 categories: (i) spontaneous
activity, (normal = 3, akinesia = 0); (ii) side stroking (bi-
lateral brisk response = 3, no response = 0); (iii) vibrissae
touch (bilateral brisk response = 3, no response = 0); (iv)
limb symmetry (forelimb and hindlimb extended = 3,
contralateral forelimb and hindlimb completely flexed = 0);
(v) lateral turning (bilateral turning ≥ 45° = 3, no turning = 0);
(vi) forelimb walking (briskly walks forward in symmetry = 3,
cannot move on forelimbs = 0); and (vii) slope climbing
(climbs to the top of slope with prompting and strong
grip = 3, weak grips and falls off = 0).
Statistics
Group sizes were determined based on power analysis.
In our calculations we assumed a 30-50% change in the
mean, 20% standard deviation (SD), alpha of 0.05, and
power of 0.8. Based on power analysis the minimum
group sizes were 5. Peripheral leukocyte counts were
expressed as means ± SD and analyzed using an un-
paired Student t-test. Venular leukocyte adhesion, pial
arteriolar reactivity, and neurological outcome were
expressed as means ± standard error of the mean (SEM).
The effect of FTY720 on on these variables was analyzed
using one-way analysis of variance (ANOVA). Signifi-
cance was defined as P < 0.05.
Results
Physiological variables for the SAH animal model
The overall mortality after SAH was approximately 30%.
Of the animals that survived the SAH surgery, one ani-
mal died in the SAH-vehicle group and one in the SAH-
FTY720 group. Blood pressure, body temperature, and
blood gas parameters were similar in the four groups.
CBF decreased abruptly by 85 to 90% after SAH. The
nadir occurred within the first minute of SAH and this
was followed by a gradual recovery reaching a plateau at
approximately 60% of baseline values within 20 minutes.
The cerebral hemodynamic responses were comparable
in both the vehicle- and FTY720-groups. SAH was also
confirmed by post -mortem visual inspection (Figure 1).
Effect of FTY720 on circulating blood cell counts
The treatment with a single dose of 0.5 mg/kg FTY720
in non-surgical animals resulted in a steep decrease in
circulating white blood cells at both 24 hours and 48
hours (Figure 2A). This decrease was largely driven by
lymphocyte depletion, which decreased to 15% and 12%
from the basal levels measured at 24 hours and 48 hours
post-treatment, respectively (P < 0.001). Blood samples
in sham and SAH-exposed animals were obtained at
baseline and 48 hours after surgery. In comparison to
Figure 1 Experimental model. (A) Representative post-mortem
examinations of brains isolated from vehicle-sham controls and
vehicle-SAH animals. (B) Cerebral blood flow (CBF) measured in the
sham-vehicle (closed circles), sham-FTY720 (open circles), SAH-
vehicle (closed squares), and SAH-FTY720 (opened squares) groups.
Time zero represents the time of surgery. The SAH-FTY720 group
was treated 3 hours after surgery. n = 10 to 11 per group. SAH,
subarachnoid hemorrhage.
Figure 2 Peripheral leukocyte cell count. Non-surgical animals
(n = 3) received a single dose of fingolimod (0.5 mg/kg) and peripheral
blood obtained at baseline, 24 hours and 48 hours post-treatment (A).
Peripheral venous blood was also obtained from sham-vehicle,
sham-FTY720, SAH- vehicle and SAH-FTY720 animals at baseline
(B) and 2 days after surgery (C) (n = 5 to 6 per group). Leukocyte cell
counts were determined as indicated in Methods. Statistical significance
was determined by Student t-test. Bars represent means ± SD. *P < 0.001
versus baseline. **P < 0.001 versus vehicle-sham. # P < 0.05 versus
Vehicle-SAH. SAH, subarachnoid hemorrhage.
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3 hours after sham- or SAH-surgery was associated with
a statistically significant decrease in total leukocytes and
lymphocytes in peripheral blood (Figure 2B and C).
Leukocyte adhesion
Circulating leukocytes were tagged with R6G and video-
recorded at 48 hours post-SAH. Representative frames were
captured from video-recordings (Figure 3). Leukocyte-
adhesion in the sham-vehicle and sham-FTY720 groups
were 2.9 ± 0.2% and 1.3 ± 0.5%, respectively. Vehicle-SAH
animals displayed almost an approximately 5-fold increase
in vascular leukocyte adhesion to pial venules compared
to controls (14.4 ± 1.0%; P < 0.0001). Treatment with
FTY720, on the other hand, was associated with a de-
creased SAH-induced leukocyte adhesion by approxi-
mately 40% (8.8 ± 2.2%).
Arteriolar reactivity
Cerebral microvascular dilating function was determined
by assessing arteriolar reactivity to established vasodila-
tors, including hypercapnia (PaCO2 at approximately 70
mmHg), Ach (10 μM and 100 μM), ADO (10 μM and100 μM), and SNAP (0.1 μM and 1 μM). Time-dependent
alterations in arteriolar reactivity occur in SAH [22]. These
changes reach their maximum 48 hours and gradually re-
cover in the following 7 days after the hemorrhage. Hence,
arteriolar reactivity was determined at 48 hours post-SAH.
Figure 3 Leukocyte vascular adhesion. Animals were treated with
vehicle or FTY720 (0.5 mg/kg) 3 hours post-surgery and leukocyte
adhesion was determined at 48 hours. (A) Representative pictures of
the vessel anatomy (bright field) and the trafficking of leukocytes (dark
field) 1 hour after leukocyte labeling with R6G in sham-vehicle, sham-
FTY720, SAH-vehicle, and SAH-FTY720-treated animals. (B) Quantification
of leukocyte adhesion, expressed as the percentage of the vessel area
occupied by adherent leukocytes measured 1 hour after leukocyte
labeling. Bars represent means ± SEM. n = 6 each group. Significance
was determined using ANOVA. SAH, subarachnoid hemorrhage.
Xu et al. Journal of Neuroinflammation  (2015) 12:16 Page 5 of 9The arteriolar responses in the sham-vehicle and sham-
FTY720 were comparable. SAH-vehicle animals showed
a profound attenuation of pial arteriolar responses to all
the vasodilators tested. In comparison, SAH-FTY720 ani-
mals displayed a statistically significant preservation of
arteriolar dilating function to all the agents investigated
(Figure 4). The improvement was partial for hypercapnia
and virtually complete for Ach, ADO, and SNAP.
Neurological outcome
Functional outcome was determined at 48 hours post-
SAH (Figure 5). The neurological score in sham-vehicle
and sham-FTY720 groups were not statistically different
(20.5 ± 0.4 versus 20.6 ± 0.4). In comparison, the score
was reduced to 11.4 ± 2.4 in the SAH-vehicle group.
The treatment with FTY720 at 3 hours after SAH was
associated with an improvement of 35% in neurological
outcome (15.5 ± 1.8; P < 0.0001).
Discussion
In this study we demonstrated that the use of fingolimod
was associated with a restricted leukocyte adhesion topial vessels, preserved arteriolar vasodilation responses,
and improved neurological function after SAH.
FTY720 has been used with success in models of cere-
bral ischemia and parenchymal hemorrhage [15-17].
This, however, is the first study addressing the protective
effect of this drug in animals subjected to SAH. The
dose of FTY720 is in agreement with studies done in
non-SAH models [15,17,23,24]. SAH is characterized by
acute headache resulting in patients seeking early medical
attention. Therefore, the 3 hours post-SAH treatment time
point constitutes a therapeutic window similar to that en-
countered in clinical practice.
FTY720 is an agonist of S1P receptors type 1, 3, 4 and
5 which are ubiquitously distributed in cells of different
lineages. Fingolimod induces the internalization and
subsequent ubiquitination and proteosomal degradation
of S1P-receptor type 1 on lymphocytes, which are
retained in lymph organs [25]. In our study, FTY720 de-
creased circulating lymphocytes with virtually no effect
on neutrophils, an observation that is consistent with
the known mechanism of action of this drug [25,26].
FTY720 has a high volume of distribution and its half-
life is of approximately 9 to 10 days [14]. Thus, it was
not unexpected that a single dose of this drug led to an
immunosuppressive state that persisted for at least 48
hours. In addition, the treatment with FTY720 restricted
the adhesion of leukocytes to pial vessels and improved
neurological outcome after SAH. The role of leukocytes
in SAH is not well known. Immediately after SAH, there
is a rapid increase in the ICP leading to transient global
hypoperfusion with subsequent restoration of the cere-
bral blood flow [27]. In this context, SAH has some
similarities with transient cerebral ischemia. Studies per-
formed in ischemic models illustrate that tissue hypoxia
upregulates the expression of adhesion molecules that
facilitate the interaction of circulating leukocytes with
vascular elements. These release vasoactive and pro-
inflammatory mediators that contribute to brain damage
[10,28,29]. In SAH, the initial insult induces an inflamma-
tory state characterized by early recruitment of leukocytes
and increased production of cytokines and chemokines in
both plasma and CSF [9,12,30]. This immune response
correlates with SAH severity and has been linked to neural
cell injury, BBB dysfunction and delayed cerebral ischemia
[31-33]. Accordingly, immunomodulation has emerged as
a potential treatment strategy that could ameliorate brain
injury and improve outcome after SAH. Our previous
findings indicate that blocking leukocyte adhesion and
transmigration into the brain parenchyma via LJP-1586, a
selective vascular adhesion protein-1 (VAP-1) inhibitor,
improves neurological outcome in SAH [34]. LJP-1586 is
nonspecific and inhibits the adhesion of neutrophils,
monocytes and lymphocytes. In comparison, FTY720 has
a selective effect on lymphocytes. Studies performed in
Figure 4 Pial arteriolar dilating reponses. Animals were treated with vehicle or FTY720 (0.5 mg/kg) 3 hours post-surgery. Measurements were
done at 48 hours after. Compared to SAH-vehicle, SAH-FTY720 animals had improved pial arteriolar vasodilating responses to all the vasodilators
tested. (A) hypercapnia (PaCO2 at approximately 70 mmHg) (P < 0.001). (B) acetylcholine, Ach (*P = 0.003; **P = 0.002). (C) adenosine, ADO
(*P = 0.002; **P < 0.001). (D) S-nitroso-N-acetyl penicillamine, SNAP (*P = 0.007; **P < 0.001). Bars represent means ± SEM. n = 5 to 6 each group.
Significance was determined using ANOVA.
Figure 5 Neurological score. Animals were treated with vehicle or
FTY720 (0.5 mg/kg) 3 hours post-SAH and the neurological score
determined at 48 hours after SAH. N = 10 to 11 each group.
Significance was determined using ANOVA.
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and adaptive immunity to stroke outcome. Understanding
the role of lymphocytes in cerebral ischemia is con-
founded by the existence of specific subpopulations that
are either protective, deleterious, or both [29]. Despite the
limited information regarding the specific contribution of
lymphocytes to SAH outcome, the selective effect of
FTY720 supports the key role of this cell type on SAH-
associated brain injury. Animal models, however, do not
necessarily recapitulate the complex pathogenic mecha-
nisms that take place in humans. From the immunological
standpoint, the predominant circulating leukocytes in
humans are neutrophils (50 to 70%) and in rodents lym-
phocytes (60 to 80%) [35]. In addition, immune-related
molecules are differentially expressed in different species
[35]. Therefore, the results obtained in experimental
models may not necessarily apply to humans. Both simi-
larities and differences have been described in the immune
responses triggered by SAH in rodents and humans [31].
Significantly, it was observed that methylprednisolone, a
drug that preferentially targets lymphocytes, is beneficial
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were too small to draw solid conclusions but they support
the active role of lymphocytes in SAH-associated brain
injury.
In our study we also observed that the use of FTY720
preserved microvascular dilating function which was
tested using different vasodilating agents. Hypercapnia
and Ach induce cerebral arteriolar dilation via nitric
oxide (NO) synthase/cyclooxygenase and endothelium-
dependent mechanisms, respectively. In comparison, ADO
tests G-coupled receptor-dependent vascular smooth
muscle responses and SNAP interrogates vascular smooth
muscle NO reactivity. Time-dependent alterations in the
response of small arteries to vasodilators occur within mi-
nutes of the SAH and peak at 48 hours [22]. The upstream
processes governing vascular tone on SAH are not com-
pletely understood. An association between inflammation
and abnormal vasomotor responses in SAH has been
established in large conduit arteries [39,40]. Lymphocytes,
in particular, have been associated with the emergence of
late vasospasm [41]. Pharmacological blockage of VAP-1
and neutrophil inhibition, in addition, ameliorate micro-
vascular dysfunction in animal models suggesting that im-
munological factors regulate vasoreactivity in both small
and large intracranial vessels [39]. Interestingly, there is
evidence supporting the notion that microvascular dys-
function is a major contributor to microthrombi forma-
tion, tissue hypoxia, and outcome after SAH [42-44]. The
improvement in neurological outcome, in parallel with de-
creased neuroinflammation and preserved arteriolar re-
sponses observed in association with FTY720, is in
agreement with this paradigm. It should be pointed out,
however, that this drug has a direct stabilizing effect on
the endothelium and has been shown to enhance the
endothelial synthesis of NO in non-neural tissues [14,45].
In our study the arteriolar responses in the sham-vehicle
and sham-FTY720 were comparable (P > 0.05) indicating
that, under the conditions used in this study, FTY720
does not have a direct vasodilating effect. FTY720 has a
direct epigenetic effect via histone deacetylases regulation
and also targets different components of the neurovascu-
lar unit. In particular, it inhibits astrogliosis, increases
neuronal survival in cerebral ischemia, and enhances
endothelial-barrier function [25,46-48]. Therefore, the
preserved arteriolar function and neurological improve-
ment observed in our study cannot be conclusively as-
cribed to the inhibition of lymphocytes.
Studies done in ischemia models demonstrate that
FTY720 decreases brain edema, reduces neuronal cell
death, and improves long-term neurobehavioral outcome
[15,17,49] Furthermore, the early treatment of intracerebral
hemorrhage patients with FTY720 reduces hematoma-
associated edema and improves neurological outcome at 3
months [50]. Since SAH is associated with uniquepathogenic mechanisms, the extrapolation of findings
gathered in other stroke models should be done with cau-
tion. Current data, however, demonstrate that FTY720 has
pleiotropic effects and can influence key elements of SAH,
including neuronal survival, BBB permeability, neuroin-
flammation, and microvascular dysfunction [15,17,49].
Similar to other brain-injury models, a profound
immunodepression develops in SAH patients [51]. This
temporary state lasts for at least 3 days after the bleed
and is associated with a high rate of infections, particu-
larly pneumonia. Thus, the potential translation of our
findings to clinical practice may be limited by the immu-
nomodulatory nature of fingolimod. Fingolimod is
known to retain naïve T cells and central memory T cells
in lymph nodes. However, this drug has a partial effect
on peripheral effector memory T cells, which are import-
ant against infections [14]. There is limited information
regarding the effect of fingolimod on infection rates on
stroke. However, studies done in the rodent model of
cerebral ischemia have shown that treatment with fingo-
limod reduces circulating leukocytes and improves out-
come without increasing the rate of bacterial lung
infections [52]. In addition, two recent small studies in-
vestigating the effect of fingolimod on patients with is-
chemic stroke and intracerebral hemorrhage showed
similar rates of infection in both the treatment and pla-
cebo groups [50,53].Conclusion
Early treatment with fingolimod after SAH reduces
leukocyte adhesion to pial venules, preserves arteriolar
dilation function, and improves neurological outcome.
Further studies are needed to determine the long-term
effect of fingolimod on SAH outcome.
Abbreviations
Ach: Acetylcholine; ADO: Adenosine; ANOVA: Analysis of variance; BBB: Blood
brain barrier; CCA: Common carotid artery; CSF: Cerebrospinal fluid;
ECA: External carotid arteries; FDA: Food and drug administration;
FTY720: Fingolimod; ICA: Internal carotid artery; ICP: Intracranial pressure;
IP: Intraperitoneal; LDF: Laser doppler flowmetry; MCA: Middle cerebral artery;
NO: Nitric oxide; PTFE: Polytetrafluoroethylene; R6G: Rhodamine-6G;
rCBF: Regional cerebral blood flow; S1P: Sphingosine-1-phosphate;
SAH: Subarachnoid hemorrhage; SNAP: S-nitroso-N-acetyl penicillamine;
VAP-1: Vascular adhesion protein-1.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
HLX and FDT were involved in the design of the study, carried out the
experiments, and participated in the data analysis and manuscript
preparation. DAP and CP participated in the data analysis and manuscript
preparation. All authors read and approved the final manuscript.
Ackowledgements
Funded by minority recruitment supplement at UIC to FDT and R01-NS063279-04
from the NIH to DAP.
Xu et al. Journal of Neuroinflammation  (2015) 12:16 Page 8 of 9Author details
1Neuroanesthesia Research Laboratory, University of Illinois College of
Medicine, Chicago, IL, USA. 2Department of Anesthesiology of the University
of Illinois College of Medicine, Chicago, IL, USA. 3Department of Neurology
and Rehabilitation of the University of Illinois College of Medicine, 912 S
Wood Street, Rm 855 N NPI (MC 796), Chicago, IL 60612-7330, USA.
Received: 21 August 2014 Accepted: 1 January 2015
References
1. Huang J, van Gelder JM. The probability of sudden death from rupture of
intracranial aneurysms: a meta-analysis. Neurosurgery. 2002;51:1101–5.
discussion 1105–7.
2. Hop JW, Rinkel GJ, Algra A, van Gijn J. Case-fatality rates and functional
outcome after subarachnoid hemorrhage: a systematic review. Stroke.
1997;28:660–4.
3. Mayer SA, Kreiter KT, Copeland D, Bernardini GL, Bates JE, Peery S, et al.
Global and domain-specific cognitive impairment and outcome after
subarachnoid hemorrhage. Neurology. 2002;59:1750–8.
4. Suarez JI, Tarr RW, Selman WR. Aneurysmal subarachnoid hemorrhage.
N Engl J Med. 2006;354:387–96.
5. Johnston SC, Mendis S, Mathers CD. Global variation in stroke burden and
mortality: estimates from monitoring, surveillance, and modelling. Lancet
Neurol. 2009;8:345–54.
6. Macdonald RL, Jaja B, Cusimano MD, Etminan N, Hanggi D, Hasan D, et al.
SAHIT Investigators - on the outcome of some subarachnoid hemorrhage
clinical trials. Transl Stroke Res. 2013;4:286–96.
7. Macdonald RL. Delayed neurological deterioration after subarachnoid
haemorrhage. Nat Rev Neurol. 2014;10:44–58.
8. Schneider UC, Schiffler J, Hakiy N, Horn P, Vajkoczy P. Functional analysis of
Pro-inflammatory properties within the cerebrospinal fluid after subarachnoid
hemorrhage in vivo and in vitro. J Neuroinflammation. 2012;9:28. 2094-9-28.
9. Kooijman E, Nijboer CH, van Velthoven CT, Mol W, Dijkhuizen RM, Kesecioglu J,
et al. Long-term functional consequences and ongoing cerebral inflammation
after subarachnoid hemorrhage in the rat. PLoS One. 2014;9:e90584.
10. Tobin MK, Bonds JA, Minshall RD, Pelligrino DA, Testai FD, Lazarov O.
Neurogenesis and inflammation after ischemic stroke: what is known and
where we go from here. J Cereb Blood Flow Metab. 2014;34:1573–84.
11. Fassbender K, Hodapp B, Rossol S, Bertsch T, Schmeck J, Schutt S, et al.
Inflammatory cytokines in subarachnoid haemorrhage: association with
abnormal blood flow velocities in basal cerebral arteries. J Neurol Neurosurg
Psychiatry. 2001;70:534–7.
12. Lad SP, Hegen H, Gupta G, Deisenhammer F, Steinberg GK. Proteomic
biomarker discovery in cerebrospinal fluid for cerebral vasospasm following
subarachnoid hemorrhage. J Stroke Cerebrovasc Dis. 2012;21:30–41.
13. Soliven B, Miron V, Chun J. The neurobiology of sphingosine 1-phosphate
signaling and sphingosine 1-phosphate receptor modulators. Neurology.
2011;76:S9–14.
14. Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G,
et al. Fingolimod (FTY720): discovery and development of an oral drug to
treat multiple sclerosis. Nat Rev Drug Discov. 2010;9:883–97.
15. Wei Y, Yemisci M, Kim HH, Yung LM, Shin HK, Hwang SK, et al. Fingolimod
provides long-term protection in rodent models of cerebral ischemia. Ann
Neurol. 2011;69:119–29.
16. Rolland 2nd WB, Manaenko A, Lekic T, Hasegawa Y, Ostrowski R, Tang J,
et al. FTY720 is neuroprotective and improves functional outcomes after
intracerebral hemorrhage in mice. Acta Neurochir Suppl. 2011;111:213–7.
17. Hasegawa Y, Suzuki H, Sozen T, Rolland W, Zhang JH. Activation of
sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after
ischemic stroke in rats. Stroke. 2010;41:368–74.
18. Sugawara T, Ayer R, Jadhav V, Zhang JH. A new grading system evaluating
bleeding scale in filament perforation subarachnoid hemorrhage rat model.
J Neurosci Methods. 2008;167:327–34.
19. Xu HL, Paisansathan C, Pelligrino DA. Closed cranial window applications in
the rat: studies on neurovascular coupling involving pial arterioles and the
glia limitans. In: Zhao M et al., editors. Neurovascular coupling methods.
New York: Springer Science+Business Media; 2014. p. 179–200.
20. Xu HL, Baughman VL, Pelligrino DA. Estrogen replacement treatment in
diabetic ovariectomized female rats potentiates postischemic leukocyte
adhesion in cerebral venules. Stroke. 2004;35:1974–8.21. Xu HL, Galea E, Santizo RA, Baughman VL, Pelligrino DA. The key role of
caveolin-1 in estrogen-mediated regulation of endothelial nitric oxide
synthase function in cerebral arterioles in vivo. J Cereb Blood Flow Metab.
2001;21:907–13.
22. Britz GW, Meno JR, Park IS, Abel TJ, Chowdhary A, Nguyen TS, et al. Time-
dependent alterations in functional and pharmacological arteriolar reactivity
after subarachnoid hemorrhage. Stroke. 2007;38:1329–35.
23. Rolland WB, Lekic T, Krafft PR, Hasegawa Y, Altay O, Hartman R, et al.
Fingolimod reduces cerebral lymphocyte infiltration in experimental models
of rodent intracerebral hemorrhage. Exp Neurol. 2013;241:45–55.
24. Hasegawa Y, Suzuki H, Altay O, Rolland W, Zhang JH. Role of the
sphingosine metabolism pathway on neurons against experimental cerebral
ischemia in rats. Transl Stroke Res. 2013;4:524–32.
25. Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in
multiple sclerosis. Clin Neuropharmacol. 2010;33:91–101.
26. Liesz A, Sun L, Zhou W, Schwarting S, Mracsko E, Zorn M, et al. FTY720
reduces post-ischemic brain lymphocyte influx but does not improve
outcome in permanent murine cerebral ischemia. PLoS One. 2011;6:e21312.
27. Sabri M, Lass E, Macdonald RL. Early brain injury: a common mechanism in
subarachnoid hemorrhage and global cerebral ischemia. Stroke Res Treat.
2013;2013:394036.
28. Chamorro A, Meisel A, Planas AM, Urra X, van de Beek D, Veltkamp R. The
immunology of acute stroke. Nat Rev Neurol. 2012;8:401–10.
29. Iadecola C, Anrather J. The immunology of stroke: from mechanisms to
translation. Nat Med. 2011;17:796–808.
30. Kubota T, Handa Y, Tsuchida A, Kaneko M, Kobayashi H, Kubota T. The
kinetics of lymphocyte subsets and macrophages in subarachnoid space
after subarachnoid hemorrhage in rats. Stroke. 1993;24:1993–2000.
discussion 2000–1.
31. Kooijman E, Nijboer CH, van Velthoven CT, Kavelaars A, Kesecioglu J,
Heijnen CJ. The rodent endovascular puncture model of subarachnoid
hemorrhage: mechanisms of brain damage and therapeutic strategies.
J Neuroinflammation. 2014;11:2. 2094-11-2.
32. Kasius KM, Frijns CJ, Algra A, Rinkel GJ. Association of platelet and leukocyte
counts with delayed cerebral ischemia in aneurysmal subarachnoid
hemorrhage. Cerebrovasc Dis. 2010;29:576–83.
33. McMahon CJ, Hopkins S, Vail A, King AT, Smith D, Illingworth KJ, et al.
Inflammation as a predictor for delayed cerebral ischemia after aneurysmal
subarachnoid haemorrhage. J Neurointerv Surg. 2013;5:512–7.
34. Xu HL, Garcia M, Testai F, Vetri F, Barabanova A, Pelligrino DA, et al.
Pharmacologic blockade of vascular adhesion protein-1 lessens neurologic
dysfunction in rats subjected to subarachnoid hemorrhage. Brain Res.
2014;1586:83–9.
35. Mestas J, Hughes CC. Of mice and not men: differences between mouse
and human immunology. J Immunol. 2004;172:2731–8.
36. Gomis P, Graftieaux JP, Sercombe R, Hettler D, Scherpereel B, Rousseaux P.
Randomized, double-blind, placebo-controlled, pilot trial of high-dose
methylprednisolone in aneurysmal subarachnoid hemorrhage. J Neurosurg.
2010;112:681–8.
37. Chyatte D, Fode NC, Nichols DA, Sundt Jr TM. Preliminary report: effects of
high dose methylprednisolone on delayed cerebral ischemia in patients at
high risk for vasospasm after aneurysmal subarachnoid hemorrhage.
Neurosurgery. 1987;21:157–60.
38. Chyatte D, Sundt Jr TM. Response of chronic experimental cerebral vasospasm
to methylprednisolone and dexamethasone. J Neurosurg. 1984;60:923–6.
39. Pradilla G, Chaichana KL, Hoang S, Huang J, Tamargo RJ. Inflammation and
cerebral vasospasm after subarachnoid hemorrhage. Neurosurg Clin N Am.
2010;21:365–79.
40. Chaichana KL, Pradilla G, Huang J, Tamargo RJ. Role of inflammation
(leukocyte-endothelial cell interactions) in vasospasm after subarachnoid
hemorrhage. World Neurosurg. 2010;73:22–41.
41. Pradilla G, Wang PP, Legnani FG, Ogata L, Dietsch GN, Tamargo RJ.
Prevention of vasospasm by anti-CD11/CD18 monoclonal antibody therapy
following subarachnoid hemorrhage in rabbits. J Neurosurg. 2004;101:88–92.
42. Friedrich B, Muller F, Feiler S, Scholler K, Plesnila N. Experimental
subarachnoid hemorrhage causes early and long-lasting microarterial
constriction and microthrombosis: an in-vivo microscopy study. J Cereb
Blood Flow Metab. 2012;32:447–55.
43. Sun BL, Zheng CB, Yang MF, Yuan H, Zhang SM, Wang LX. Dynamic
alterations of cerebral pial microcirculation during experimental
subarachnoid hemorrhage. Cell Mol Neurobiol. 2009;29:235–41.
Xu et al. Journal of Neuroinflammation  (2015) 12:16 Page 9 of 944. Ostergaard L, Aamand R, Karabegovic S, Tietze A, Blicher JU, Mikkelsen IK,
et al. The role of the microcirculation in delayed cerebral ischemia and
chronic degenerative changes after subarachnoid hemorrhage. J Cereb
Blood Flow Metab. 2013;33:1825–37.
45. Tolle M, Levkau B, Keul P, Brinkmann V, Giebing G, Schonfelder G, et al.
Immunomodulator FTY720 induces eNOS-dependent arterial vasodilatation
via the lysophospholipid receptor S1P3. Circ Res. 2005;96:913–20.
46. Hait NC, Wise LE, Allegood JC, O’Brien M, Avni D, Reeves TM, et al. Active,
phosphorylated fingolimod inhibits histone deacetylases and facilitates fear
extinction memory. Nat Neurosci. 2014;17:971–80.
47. Brunkhorst R, Vutukuri R, Pfeilschifter W. Fingolimod for the treatment of
neurological diseases-state of play and future perspectives. Front Cell
Neurosci. 2014;8:283.
48. Xiong Y, Hla T. S1P control of endothelial integrity. Curr Top Microbiol
Immunol. 2014;378:85–105.
49. Campos F, Qin T, Castillo J, Seo JH, Arai K, Lo EH, et al. Fingolimod reduces
hemorrhagic transformation associated with delayed tissue plasminogen
activator treatment in a mouse thromboembolic model. Stroke.
2013;44:505–11.
50. Fu Y, Hao J, Zhang N, Ren L, Sun N, Li YJ, et al. Fingolimod for the
treatment of intracerebral hemorrhage: A 2-arm proof-of-concept study.
JAMA Neurol. 2014;71:1092–101.
51. Sarrafzadeh A, Schlenk F, Meisel A, Dreier J, Vajkoczy P, Meisel C.
Immunodepression after aneurysmal subarachnoid hemorrhage. Stroke.
2011;42:53–8.
52. Pfeilschifter W, Czech-Zechmeister B, Sujak M, Foerch C, Wichelhaus TA,
Pfeilschifter J. Treatment with the immunomodulator FTY720 does not
promote spontaneous bacterial infections after experimental stroke in mice.
Exp Transl Stroke Med. 2011;3:2. 7378-3-2.
53. Fu Y, Zhang N, Ren L, Yan Y, Sun N, Li YJ, et al. Impact of an immune
modulator fingolimod on acute ischemic stroke. Proc Natl Acad Sci U S A.
2014;111:18315–20.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
